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Abstract: Coxsackie B (CVB) viruses have been associated with type 1 diabetes. We have recently
observed that CVB1 was linked to the initiation of the autoimmune process leading to type 1 diabetes in
Finnish children. Viral persistency in the pancreas is currently considered as one possible mechanism.
In the current study persistent infection was established in pancreatic ductal and beta cell lines
(PANC-1 and 1.1B4) using four different CVB1 strains, including the prototype strain and three
clinical isolates. We sequenced 5′ untranslated region (UTR) and regions coding for structural and
non-structural proteins and the second single open reading frame (ORF) protein of all persisting
CVB1 strains using next generation sequencing to identify mutations that are common for all of these
strains. One mutation, K257R in VP1, was found from all persisting CVB1 strains. The mutations
were mainly accumulated in viral structural proteins, especially at BC, DE, EF loops and C-terminus
of viral capsid protein 1 (VP1), the puff region of VP2, the knob region of VP3 and infection-enhancing
epitope of VP4. This showed that the capsid region of the viruses sustains various changes during
persistency some of which could be hallmark(s) of persistency.
Keywords: type 1 diabetes; enterovirus; coxsackievirus B1; next generation sequencing; persistent
infection; cell models of persistency; virus adaptation
1. Introduction
Coxsackie B group viruses (CVBs) belong to Enterovirus (EV) genus in the family of Picornaviridae.
EVs have positive-sense single-stranded RNA genomes, approximately 7400 nucleotides (nt) long,
inside a 30 nm icosahedral protein capsid [1]. The protein capsid consists of 12 pentameric subunits,
built up of five protomers. Each protomer contains viral structural proteins VP1-4. EVs have fivefold,
threefold, and twofold symmetry axes. The VP1 protein is located around fivefold axes, whereas VP2
and 3 are found around threefold axes. EVs have a deep depression, called the canyon, which encircles
the fivefold axes below VP1. Often the canyon is a receptor binding site [2,3]. A possible externalization
site for the RNA genome is located near the twofold axes [4].
The EV genome was long thought to contain only a single open reading frame (ORF), which is
proteolytically processed into four structural proteins (VP1-4) and into seven non-structural proteins
(2A-2C and 3A-3D). However, recent studies have identified another ORF harbored upstream, hereafter
called the second ORF (ORF2) [5,6]. The ORF2 is translated into a protein called ORF2 protein (ORF2p),
which has been proposed to have a role in virus growth in gut epithelial cells. The viral genome has
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untranslated regions (UTRs) at each end. The 5′-UTR is long (740 nt), highly conserved and it has
important functions in viral replication. It contains the internal ribosome entry site (IRES) of the virus
and is covalently attached to a small protein called viral protein genome linked (VPg) [7]. The 3′-UTR
is flanked by a poly-A tail and is important in (-) strand synthesis [8].
Typically, CVBs cause acute illnesses such as common cold, encephalitis, meningitis, myocarditis,
herpangina, pancreatitis and hepatitis [9]. Additionally, CVBs have been shown to establish persistent
infections [10–13] which have been linked to the pathogenesis of certain chronic diseases including
e.g., chronic cardiomyopathies, type 1 diabetes (T1D) and post-polio syndrome [14–17].
The association between CVBs and T1D has been shown in several studies including serological
studies and direct virus detection [18–21]. CVBs include six different serotypes (CVB 1-6) and CVB1
is one of the serotypes that has associated with increased risk of T1D [19]. Currently, the most
plausible hypothesis is that a persistent infection in the insulin-producing pancreatic beta cells leads to
cell-damage either by a direct viral effect or via virus-induced inflammation [22–26].
EVs have previously been thought to cause lytic infections. However, it has become evident
that EVs can also persist in cells and tissues [10,13,23,27]. The exact mechanism of EV persistency
in cultured cells is not known, but seemingly it requires co-evolution of both the host cell and the
infecting virus [11,28]. Two different types of EV persistency have been proposed to exist, a carrier
state and a steady state persistency. In carrier state persistency, only a small proportion of the cells are
infected, but the virus is produced in relatively high titers [11,28]. In steady state persistency, on the
other hand, nearly all the cells are infected, but the virus is unable to complete lytic replication [29].
Steady state persistency has been linked to terminal deletions, of 7 to 49 nts long, in the 5′-UTR of the
viral genome [27].
We have previously characterized cellular adaptation during the development of CVB1 persistency
using proteomics approach [30]. This study aims at identifying the changes that occur in the CVB1
genome during the development of persistence. To this end, we have established persistent infection
in pancreatic ductal cell line (PANC-1) with four strains of CVB1, and in pancreatic beta cell line (1.1B4)
with three strains of CVB1 to identify mutations that are common in all these persistence models.
The genome modifications of each persistent infection-derived virus (PIDV) were characterized using
next generation sequencing methods (NGS).
2. Materials and Methods
2.1. Persistent Infection
Four strains of CVB1 were used to establish altogether eight persistent models in two pancreatic
cell lines: in pancreatic ductal cell line, PANC-1, and in pancreatic beta cell line, 1.1B4 (mycoplasma-free
cell lines were obtained from American type culture collection, ATCC, Manassas, VA, USA). The four
CVB1 strains included Conn-5 a prototype strain, later referred as ATCC (obtained from the ATCC)
and three clinical isolates 10796 (Argentina 1983), 10797 (United States, Connecticut, 1984) and 10802
(Argentina 1998) [31]. All four strains were used to establish persistent infection in PANC-1 cells and
three of the strains CVB1 ATCC, 10796 and 10802 were used to establish a persistent infection in 1.1B4
cells. CVB1 ATCC virus has established duplicated biological model on PANC-1 cells named E1 and
E2. The PIVD are named as “strain code-PIDV[Cell line]” in this publication.
The persistent infection was established using a protocol earlier described by Sane et al. for CVB4
E2 [10] also as described in our previous publications [30,32]. After the initial infection the cells were
washed three times a week. The cells were harvested once a week after they had started to grow
after the initial lytic phase of infection. In addition, in the CVB1 ATCC and 10796 persistent infection
models on PANC-1 cells, an additional transfer of cells on fresh PANC-1 cells was done 2–4 weeks
after the initial infection. Presence of the virus genome and infectious virus particles were verified
using RT-qPCR [33,34], and virus plaque formation [18] from different timepoints during persistency.
The plaque morphology was also studied.
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Immunofluorescent Labeling
Virus infected cells were identified by immunofluorescent labeling. Persistently infected cells
were harvested 3.4–4.7 and 12.7–14.2 months post-infection by scraping, and cell pellets were fixed in
10% formalin (Oy FF-Chemicals Ab, Haukipudas, Finland) for 24 h prior to dehydration and paraffin
embedding. The formalin-fixed paraffin-embedded (FFPE) samples were immunostained using two
different antibodies; an in-house generated monoclonal rat antibody, clone 3A6, (kindly provided by
professor Vesa Hytönen, Tampere University), which identifies an epitope in the N-terminal region of
EV-VP1 [35], and J2, a commercial monoclonal mouse antibody (SCICONS English & Scientific Consulting
Kft., Szirák, Hungary) [36], which detects virus dsRNA (a byproduct of the virus replication). Commercial
goat anti-rat 568 and anti-mouse 488 IgG (H + L) Alexa Fluor (Thermo Fisher Scientific, Waltham, MA, USA)
secondary antibodies were used for detection. Imaging was performed using an Olympus BX-60 microscope.
2.2. Next Generation Sequencing
Cell culture supernatants were collected from three time points: one day post infection (time point
0; TP0), and approximately 5–7 and 12-months post infection TP1 and TP2, respectively. Virus RNA
was extracted using QIAamp Viral RNA Mini kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instruction directly from cell culture supernatant. Sample preparation and NGS
were performed as described elsewhere [37,38]. The RNA was reverse transcribed with ImProm II
reverse transcriptase (Promega, Madison, WI, USA), the second strand synthesis was performed by
adding 5’-end exonuclease negative Klenow fragment (Promega, Madison, WI, USA). After purifying
unincorporated primers and single stranded molecules the double-stranded transcripts were amplified
using their respective invariant tags as primers by a 20 cycles’ PCR with the AmpliTaq Gold chemistry
(Applied Biosystems, Foster City, CA, USA) [37]. Size selection and purification of the pre-amplified
libraries were done using Agencourt AMPure XP (Beckman Coulter, Fullerton, CA, USA) mixed with
the product at 0.5× ratio. Nextera XT DNA Sample Preparation Kit (Illumina, San Diego, CA, USA)
was used to process the libraries in batches of twenty-four samples per sequencing run. The protocol
provided by the manufacturer was followed until the normalization step. The libraries were diluted for
sequencing according to concentrations measured by KAPA kit (Illumina, San Diego, CA, USA) before
and after the pooling, and were denaturized prior to sequencing. Sequencing of the libraries was done
on a MiSeq instrument (Illumina, San Diego, CA, USA) using the Nextera XT v2. 250 × 250-cycles
sequencing kit (Illumina, San Diego, CA, USA).
2.3. Analyzing the Sequence Data
The quality of the sequencing data was determined using FastQC-0.11.7 [39] and the sequencing
reads were trimmed according to the quality using Trimmomatic-0.36.0 [40]. BBTools-37.96 [41]
Clumpify tool was used to remove PCR and optical duplicate reads. The reads were then aligned
with BWA-0.7.17 [42] to strain-specific reference sequences which were obtained through Sanger
sequencing on the parental virus strains. The alignments were filtered for mapping quality and sorted
using Samtools-1.6. [43] while Breseq-0.31.1 [44] was run in polymorphism mode for single nucleotide
polymorphism (SNP) discovery. A threshold of 5 forward and 5 reverse-strand reads containing the
alternate allele was used before a SNP was called. In addition, the alternate allele had to appear in at
least 5% of the reads covering the position. Synonymous SNPs were filtered out with custom scripts.
Lolliplots visualizing SNPs across the genome were created with R package Trackviewer-1.16.0 [45].
Nucleotide sequences were aligned using Clustal omega online tool [46]. Nucleotide sequences were
translated into amino acid sequences and were analyzed using GeneDoc program [47].
2.4. 3D Modelling
The 3D structure was modelled based on the Sanger sequencing of the CVB1 ATCC parental virus.
At the time of initial analysis, a CVB1 3D template was not available, however, CVB3 is structurally
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similar to CVB1 therefore two CVB3 3D templated were used for modelling [48]. The capsid was 3D
modelled using CVB3 X-ray diffraction templates 4GB3 [49] and 1COV [48] obtained from Protein Data
Bank (PDB) [50]. Modelling software Modeller-9.20 was used to create 20 models [51]. The model with
the lowest discrete optimized protein energy (DOPE) score, representing the highest structural quality,
was chosen for visualization [52]. The model is visualized in ChimeraX.
3. Results
3.1. Characteristics of Established Persistent Infections
Altogether eight persistent infection models were established in two pancreatic cell lines (PANC-1
and 1.1B4), using four CVB1 strains: ATCC prototype strain (Conn-5), and three clinical isolates called
10796, 10797 and 10802. The genome copy number generally decreased immediately after the initial
infection due to cell death, but gradually increased to a steady level of 108–109 copies/mL in the
supernatant (Figure 1).
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using TCID50 assay showing the presence of infective virus in high titer (Supplementary Table S1). 
Figure 1. Geno e copy nu bers easured by RT-qPCR fro cell culture supernatants collected from
persistent infection odels over ti e. In all the odels the copy nu ber eventually stabilized to
approximately 108 to 109 copies/mL. Addition of fresh cells into three of the models is indicated by
an arrow.
Virus protein and dsR er t t i ti f t ll i unostaining in time
points 1 and 2, 3.4–4.7 and 12.7–14.2 o t s st-i f cti r s cti l ( i re 2a). The amount of
VP1 positive cells in persistent infecti as s t fl ct ate er ti e [53]. Virus positive cells
were detected in all virus infected cell cultures in both ti e points despite the mutations that occurred
in viral genome at the suspected 3 6 antibody binding site [35]. ne utation was identified in this
site in ATCC E2-PIDV[PANC-1], 10796-PIDV[PANC-1], 10796-PIDV[1.1B4], and 10802-PIDV[1.1B4] strains,
and three mutations in ATCC-PIDV[1.1B4] strain (Figure 2b). However, the effect of these mutations on
the antibody binding was not quantified. In addition, the amount of infective virus from the culture
medium of CVB1 ATCC E1, E2 and 10796 persistent infection models (PANC-1 cells) was analyzed
using TCID50 assay showing the presence of infective virus in high titer (Supplementary Table S1).
Microorganisms 2020, 8, 1790 5 of 21





Figure 2. (a) Immunostaining of persistently CVB1 infected PANC-1 and 1.1B4 cells from two-
timepoints (3.4–4.7 months post-infection in top row and 12.7–14.2 months post-infection in bottom 
row, corresponding to TP1 and TP2 respectively) and of uninfected control cells (CNTRL). VP1 
protein (red) and dsRNA (yellow), and the average proportion of cells positive for viral VP1 protein 
was 22.9 ± 13.7% at the later time point (12.7–14.2 months post-infection) ranging from 7.1 ± 0.5% in 
the CVB1 10796 persistent infection model in 1.1B4 cells to 41.7 ± 9.8% in CVB1 10797 model in PANC-
1 cells (altogether three microscopic fields were counted in each model including a total of 16,338 
cells). (b) The virus amino acid sequence of the epitope region of the 3A6 antibody used in VP1 
staining is shown for each PIDV. The red frames mark the mutations observed in CVB strains at last 
time point. 
Virus Plaque Morphology 
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development of viral persistency in all PIDVs, except in ATCC-PIDV[1.1B4] which didn’t show any 
obvious change even one-year post infection (Figure 3). The change in plaque morphology was more 
prominent in clinical isolates (10796, 10797 and 10802), which originally produced larger plaques than 
the ATCC strain (Figure 3). 
Figure 2. (a) Immunostaining of persistently CVB1 infected PANC-1 and 1.1B4 cells from two-timepoints
(3.4–4.7 months post-infection in top row and 12.7–14.2 months post-infection in bottom row,
corresponding to TP1 and TP2 respectively) and of uninfected control cells (CNTRL). VP1 protein (red)
and dsRNA (yellow), and the average proportion of cells positive for viral VP1 protein was 22.9 ± 13.7%
at the later time point (12.7–14.2 months post-infection) ranging from 7.1 ± 0.5% in the CVB1 10796
persistent infection model in 1.1B4 cells to 41.7 ± 9.8% in CVB1 10797 model in PANC-1 cells (altogether
three microscopic fields were counted in each model including a total of 16,338 cells). (b) The virus
amino acid sequence of the epitope region of the 3A6 antibody used in VP1 staining is shown for each
PIDV. The red frames mark the mutations observed in CVB strains at last time point.
Virus Plaque Morphology
Morphology of the virus plaques was identified in green monkey kidney cells (GMK) during the
development of persistent infection. The plaque morphology naturally varies between CVB1 stains,
which is seen in the first row in Figure 3. Generally, the size of the plaques decreased during the
development of viral persistency in all PIDVs, except in ATCC-PIDV[1.1B4] which didn’t show any
obvious change even one-year post infection (Figure 3). The change in plaque morphology was more
prominent in clinical isolates (10796, 10797 and 10802), which originally produced larger plaques than
the ATCC strain (Figure 3).
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3.2.1. Untranslated Regions
The read depth in the 3′-UTR was mainly below 10 in PIDV genomes (Figure 4) obtained from
NGS analysis making variant calling not possible. The read depth was above 10 in the majority of the
5′-UTR, except in the beginning in domain I, also call d as cloverleaf region (Figure 4). D mains II-V
covers th internal ribosome entry site (IRES) that controls translation [7]. The mutations observed
are randomly distributed, but majority of the mut tions l cates at positions 602–655, and at positions
691–717 (Figure 5).
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Figure 4. Lolliplots of each PIDV at the last timepoint. Single nucleotide polymorphism (SNP) are 
indicated by lollipop. All non-synonymous SNPs, and SNPs at both UTR are indicated. Grey bar 
below the genome bar characterizes the read depth (>10). (a) ATCC E1-PIDV[PANC-1]. (b) ATCC E2-
PIDV[PANC-1]. (c) 10796-PIDV[PANC-1]. (d) 10797-PIDV[PANC-1]. (e) 10802-PIDV[PANC-1]. (f) ATCC-PIDV[1.1B4]. 
(g) 10796-PIDV[1.1B4]. (h) 10802-PIDV[1.1B4]. 
 
Figure 5. Mutation in 5′-UTR. SNPs are color coded indicating different PIDVs. Six distinct domains 
of the 5′-UTR are indicated by horizontal bars. Domain I is the cloverleaf structure and the IRES covers 
the domains II-V. Domain I: base pairs 2–87; Domain II: base pairs 105–181; Domain III: base pairs 
189–209; Domain IV: base pairs 213–456; Domain V: base pairs 466–636 and Domain VI: base pairs 
651–669 [54]. 
3.2.2. Accumulation of Amino Acid Substitutions in Structural Proteins 
Amino acid (AA) sequence of each PIDV from TP2 was aligned to the parental virus strain and 
CVB3-Nancy (obtained from NCBI GeneBank, JX312064.1) for comparison. CVB3 was included in the 
analysis for its sequence similarity and known features from the literature. Non-synonymous AA 
substitutions were identified, in eight PIDV strains, from each viral structural protein compared to 
the relevant parental strains. The majority of the observed substitutions did not map to the same 
residues in all eight PIDVs, but the mutations accumulated in the similar regions of viral structural 
proteins. 
The most interesting substitution was the K257R, which was the hallmark of persistency in all 
PIDVs at TP2. This AA is located towards the C-terminus of the VP1 the alternate AA before the K259 
residue which is marked as a Coxsackie and Adenovirus receptor (CAR) binding AA footprint, a 
location which is a published immunogenic peptide (PEP91) in CVA-16 [55]. This might indicate an 
important relevant mechanism for persistency, but we did not confirm it by experiments such as side-
directed mutagenesis and persistency establishment in cell models. 
In the VP1 structural protein the mutations accumulated to the N-terminal region of VP1 (the 
suspected 3A6 antibody binding site [35]) and in four additional positions, including the region 
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Figure 5. Mutation in 5′-UTR. SNPs are color coded indicating different PIDVs. Six distinct domains of
the 5′-UTR are indicated by horizontal bars. Domain I is the cloverleaf structure and the IRES covers the
domains II-V. Domain I: base pairs 2–87; Domain II: base pairs 105–181; Domain III: base pairs 189–209;
Domain IV: base pairs 213–456; Domain V: base pairs 466–636 and Domain VI: base pairs 651–669 [54].
3.2.2. Accumulation of Amino Acid Substitutions in Structural Proteins
Amino acid (AA) sequence of each PIDV from TP2 was aligned to the parental virus strain and
CVB3-Nancy (obtained from NCBI GeneBank, JX312064.1) for comparison. CVB3 was included in
the analysis for its sequence similarity and known features from the literature. Non-synonymous AA
substitutions were identified, in eight PIDV strains, from each viral structural protein compare to t e
relevant parental strai s. The majority of the observed substitutions did not map to the same residues
in all eight PIDVs, but the mutations accumulated in the similar regions of viral structural proteins.
The most interesting substitution was the K257R, which was the hallmark of persistency in all
PIDVs at TP2. This AA is located towards the C-terminus of t e VP1 the alternate AA before the
K259 residue which is marked as a Coxsackie and Adenovirus receptor (CAR) binding AA footprint,
a location which is a published immunogenic peptide (PEP91) in CVA-16 [55]. This might indicate
an important relevant mechanism for persistency, but we did not confirm it by experiments such as
side-directed mutagenesis and persistency establishment in cell models.
In the VP1 structural protein the mutations accumulated to the N-terminal region of VP1
(the suspected 3A6 antibody binding site [35]) and in four additional positions, including the region
surrounding the BC loop (residues 81–85), the DE loop (residues 125–137), the EF loop (residues
145–165) and the C-terminus of VP1 (Figure 6). All PIDVs had at least one mutation in all of these three
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“hot spots”, except 10796-PIDV[1.1B4] which did not sustain any non-synonymous mutations around
the BC loop region, and 10802-PIDV[PANC-1] which did not have any non-synonymous mutations in
the EF loop region. Additionally, mutation R95K was detected in three PIDVs (ATCC E2-PIDV[PANC-1],
10796-PIDV[PANC-1] and 10797-PIDV[PANC-1]) and V97A in two of the PIDVs (ATCC E1-PIDV[PANC-1]
and ATCC-PIDV[1.1B4]) in the CD loop region (residues 91–97). ATCC E2-PIDV[PANC-1] had a N202K
mutation, 10802-PIDV[PANC-1] mutations R201K and N202K, and 10796-PIDV[1.1B4] had mutation
N202K, which located in the GH loop region (residues 192–214). ATCC E1-PIDV[PANC-1] had E223D
and G227S mutations and 10796-PIDV[PANC-1] A224V mutation in HI loop region (residues 222–228)
respectively. Interestingly all the strains at TP0 had similar AA sequences in the BC, DE, and EF loops,
while the persistent viruses had changed in this region.
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Shown in Figure 7a, AA substitutions accumulated in the EF loop region of the VP2 capsid
protein, also known as the “puff region” (residues 129–180). All CVB1 PIDVs had at least one mutation
in the puff region and the majority of the mutations located to residues 158-167 within this region.
Mutation G236R was found in two PIDVs (10797-PIDV[PANC-1] and 10802-PIDV[1.1B4]) and P239S
in two PIDVs (10796-PIDV[PANC-1] and ATCC-PIDV[1.1B4]) in HI loop region (residues 233–239 in
VP2). Additionally, five PIDVs had a mutation in AA70 in Bb-sheet (Q70H in 10796-PIDV[PANC-1],
10797-PIDV[PANC-1], 10802-PIDV[PANC-1] and 10796-PIDV[1.1B4]; Q70Y in ATCC-PIDV[1.1B4]).
The PIDVs, except 10802-PIDV[P -1] and 10802-PIDV[ .1B4], had mutations which accumulated
around the ajor protrusion on the P3 capsid protein (knob region, residues 58–66 in VP3) and
especially on AA58 in VP3 (Figure 7b). Additionally, the mutation in AA93 occurred in five of the PIDVs
(G93S in 10796-PIDV[PANC-1] and 10796-PIDV[1.1B4]; N93S in 10797-PIDV[PANC-1], 10802-PIDV[PAN 1]
and 108 2-PIDV[1. B4]) i t l r i (r si s 7 i P3). Also, V141A mutation was in
t re PI s includin TCC E1-PIDV[P -1], 10796-PIDV[PANC-1] and 1 802-PIDV[PANC-1], locati g
in the EF loop region (residues 136–144 in VP3). L117F mutation in Bd-sheet occurred in ATCC
E1-PIDV[PANC-1], ATCC-PIDV[1.1B4] and 10802-PIDV[1.1B4].
i , f t e uff a knob regions in the parental strains were identical and
s stablish ent. Both CAR and a decay a celerating factor (DAF)
i i t regions and the changes in these regions might have played a
role i t li
i t ti s i t e infection-enhancing epitope ( A 1-30) [56,57] on
P4 capsid protein (Figure 7c) (stains ATCC E2-PIDV[PANC-1], 10796-PIDV[PANC-1], - I [PANC-1],
108 - I [PANC-1] and 10796-PIDV[1.1B4]). AA16-24 have been reported to be the most variable
se e ce i t is re i , ic as als see i t ese I s (Figure 7c) [58].
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. . . l ti f i i tit ti i - tr t r l ir l r tei s
- tr t r l r t i i l i - - l t ti t t tr t r l
r t i . ly f f t t ti i - r r iff r t I ( l t
i r ). In 2A two PIDVs (AT C E1-PIDV[PANC-1] and ATCC-PIDV[1.1B4]) had mutation in
AA11 (respectively Y11C and Y11H) and one PIDV (10802-PIDV[PANC-1]) had a close mutation, N14T.
The 10796-PIDV[PANC-1] had six mutations in 2A, whereas other PIDVs had only 1–3 mutations.
The mutati ns of 10796-PIDV[PANC-1] included a small cluster of mutations in AA86-94 (E86G, Y89H
and Y94H).
I t ere are very few mutations (Sup lement Figure S1). One mutation, S15L, was observed in
all three CVB1 ATCC PIDVs and one of the mutations was located at the ydroph bic domain, but the
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mutation was from a hydrophobic AA to another hydrophobic AA (I50V). One mutation was located
in the hydrophilic domain (K58R, changed to functionally similar AA). Additionally, three PIDVs have
mutations in AA91-92.
In 2C protein there are only a few mutations, which include one mutation, M175L, at the ATPase
motif B in 10796-PIDV[PANC-1] and [1.1B4] (Supplement Figure S1). Additionally, three PIDVs have
mutations in AA91-92 and in AA251-259. None of these mutations were observed in the cis-acting
replication element (CRE) in the 2C protein-coding region [CRE(2C)], in which the mutations have
been shown to drive the de novo generation of genomic deletions at the 5′ terminus [59].
Among 3A-D, two of the proteins were conserved. The 3B protein (VPg), was conserved in all
PIVDs. Also, 3C protein was conserved, since only one AA substitution (Q52R) was observed in the
10802-PIDV[PANC-1]. In the 3A protein only a few mutations were observed. However, one mutation
(V58I) was in four PIDVs, including 10796-PIDV[PANC-1], 10802-PIDV[PANC-1], ATCC-PIDV[1.1B4] and
10802-PIDV[1.1B4]. In addition, ATCC E1-PIDV[PANC-1] carried the H57Y mutation, which has been
linked to resistance against antiviral drugs including enviroxime, GW5074 and PIK93 [60]. Only a
few mutations were observed in the 3D polymerase, but they were not shared by other strains and
were randomly distributed in the genome. One mutation (V230I) was located in motif A in ATCC
E1-PIDV[PANC-1] and two mutations in motifs B: S299T in 10976-PIDV[1.1B4] and I306V in ATCC
E2-PIDV[PANC-1].
3.2.4. The Second ORF
The recently published second ORF was identified from CVB1 sequences. The second ORF is
translated into the ORF2p protein. The protein has a highly conserved WIGHPV domain, which is
important for ORF2p-dependent viral intestinal infection [5,6]. WIGHPV domain was identified in all
four CVB1 strains but in the last timepoint one mutation (V18A) was observed in 10802-PIDV[1.1B4]
(Figure 8).
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3.2.5. Virus Surface Structure 
The surface of CVB1 pentameric structure was 3D modelled with ChimeraX using the structure 
of CVB3 as a template (Figure 9). 
Figure 8. ORF2p and its conserved WIGHPV domain in TP2. One mutation was observed in conserved
WIGHPV domain in 10802-PIDV[1.1B4].
3.2.5. Virus Surface Structure
The surface of CVB1 pentameric structure was 3D modelled with ChimeraX using the structure of
CVB3 as a template (Figure 9).
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B1, as ell as all other CVBs, C R for cell entry [61]. esi es , so e s, like 1,
interact F (also kno n as CD-55) [62]. bin ing site is locate in the canyon of the CVBs
hereas F bi ing site is outside the canyon. The AAs interacting with these molecules are
shown in Figure 9b [61,63–65]. The majority of the mutations in these footprint areas locate in DAF
binding site (Figure 9c). In the CAR binding site, AA202 in VP1, was mutated (N202K) in three
PIDVs (ATC E2-PIDV[PANC-1], 10802-PIDV[PANC-1] and 10796-PIDV[1.1B4]) as marked by an arrow
and the number 1 in igure 9c. In the DAF binding site, AA162 in VP2, was mutated in five PIDVs
(T162P in ATCC E1-PIDV[PANC- ], TCC-PIDV[1.1B4]; T162A in ATCC E2-PIDV[PANC- ]; E162G in
10796-PI [1. 4]; E162Q in 10802- IDV[1.1B4]), and AA237 i VP3 was mutated (Y237F) in three
PIDVs (ATCC E1-PIDV[PANC-1], ATCC E2-PIDV[PANC-1] and ATCC-PIDV[1.1B4]) (Figure 9c). The VP2
mutation in AA 165 was shared by both these binding sites and found in three PI s ( 165Y in
E1-PIDV[PANC-1] and ATCC-PIDV[1.1B4 ; S165R in 10796-PIDV[PANC-1]) as indicated by an arrow (3.) in
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Figure 9c. Mutation K257R in VP1, found in all eight PIDVs (mentioned above), is located close to the
receptor binding sites (Figure 9c). Additionally, the mutations in PIDV accumulated within the puff
region are also the ones that interact with the CVB1 receptors.
4. Discussion
The results of the present study indicate that the CVB1 strains that have adapted to viral persistence
differ from the parental CVB1 strains which have not been exposed to such selection pressure—they
produced smaller plaques and shared common mutations in their genome. Since viral persistence was
established in two different cell lines using four different CVB1 strains (altogether 8 models) we were
able to study whether any mutation occur similarly in several persisting CVB1 strains. The mutation
frequency on RNA viruses is relatively high, and ∼4 to ∼8 mutations/104 nt is well-tolerated and are
fully stable in the context of infectious virus, creating a concept called quasispecies. The upper limit
of mutation frequency that the virus can tolerate without loss of infectivity was proposed to be in
the range of 11–12 mutations/104 nt [66]. Thus, there are numerous possibilities for virus changes
during persistency. The virus may become less cytopathic e.g., by having impaired initiation of
translation, adsorption (receptor binding), internalization (uncoating) or failure in efficient host shut
off. Several studies have shown that mutations in structural proteins have an effect on virulence and
pathogenicity. Even one amino acid change in structural proteins may modulate important functions
in virus infection [67–70].
In the current study one mutation was particularly prominent—the amino acid substitution K257R
in the VP1 protein was found in all these strains. This amino acid substitution has previously been
reported in a non-lytic CVB6 Schmitt strain during a blind-passage in HPDE-cells when it acquired a
lytic phenotype with increased production of progeny virus and increased number of infected cells [71].
This amino acid is located in the canyon region of the viral capsid. The authors found also some
evidence suggesting that the mutation influenced viral interaction with DAF [71]. CVBs use CAR as
the main receptor for internalization [61,72] but CVB1, CVB3 and CVB5 bind also to DAF [73,74]. CAR
binding causes a conformational change in the viral capsid, called A-particle formation, which leads
to externalization of the viral genome into the cytoplasm. However, DAF binding does not induce
A-particle formation or cytolytic infection [75–77], but can trap the virus into the intercellular junctions
where the CAR molecules locate [72]. However, this mutation is not directly located in the DAF-binding
region of the viral capsid. On the other hand, some other mutations located in the DAF footprint
area, including the mutation T162 in VP2, which occurred in five PIDVs. Mutations in the DAF
binding-site have previously been shown to regulate the pathogenicity of CVB1 infection in a mouse
model [78,79]. Three amino acids showed variation also in the CAR footprint area. One of these
mutations (AA162 in VP2) occurred in five PIDVs. However, we have previously found that at least
some of the PIDVs (ATCC E2-PIDV[PANC-1] and 10796-PIDV[PANC-1]) are still able to use CAR as a
receptor for internalization [30]. It is possible that some of the mutations that link to development of
persistent CVB infection may regulate virus binding to the DAF and CAR molecules. Also, we do not
know if both CAR and DAF binding are modified in persistency and virus can mutate back to parental
strain upon acute infection.
In addition to the dominant K257R substitution in VP1, other mutations accumulated in structural
proteins, including N-terminal region, a suspected 3A6 antibody binding site, BC, DE, EF loops and
the C-terminus of VP1, the VP2 puff region, VP3 knob and the infection-enhancing epitope of the
VP4 [56,57]. All these regions have been linked to virus biology in previous studies. The EF loop of
VP2 (puff region; residues 129–180) and the surface protrusion of VP3 (knob region; residues 58–66)
include the neutralizing immunogenic sites in rhinoviruses [80,81] and polioviruses [82,83]; and have
receptor binding significance. Mutations in these regions have been shown to change the ability of
CVBs to induce myocarditis [79,84,85] and can alter the virulence in mice. They also regulate plaque
morphology in cell culture [86]. Mutation in these regions were common among studied PIDVs, since
all of the PIDVs had mutations in the puff region and six of the PIDVs have mutations in the knob
Microorganisms 2020, 8, 1790 15 of 21
region. The VP4 substitution in the infection-enhancing epitope region in AA16 (S16R) has been
linked to the plaque phenotype of CVB4 and to avirulence in vitro and intermediate phenotype in vivo
(mice) [87,88]. Five of the PIDVs had mutations in infection-enhancing epitope, and particularly
mutation at AA16, G16R, was observed in ATCC E2-PIDV[PANC-1]. Alidjinou et al. have studied
carrier-state persistent CVB4 infection in PANC-1 cell model. They identified non-synonymous
mutations in VP1 and VP2, structural proteins, and in non-structural proteins 2A, 2C and 3D [28],
including altogether 105 mutations, of which 40 were amino acid substitutions occurring mainly in
VP1 and 2A. No mutations were found in the CAR footprint region [28]. In the present study, the VP1
region has several mutations, and four residues with mutations accumulated in different PIDVs’.
All the PIDVs had mutations in DE loop and in the N-terminus of the VP1. The DE loop is the most
prominent exterior loop in VP1 (residues 125–137, in CVB3) found at the fivefold axis [48]. The DE
loop may stabilize the capsid and is responsible for pH stability. This is because each DE loop interacts
with other DE loops due to icosahedral symmetry; and because DE loops are involved in interactions
with putative ion-binding sites along the fivefold axis. Seven of the PIDVs had mutations in the EF
loop and surrounding the BC loop. The BC loop (residues 81–85 in CVB3), which flanks the rim of the
canyon closest to the fivefold axes [48], has been shown to be an important neutralizing immunogenic
sites for coxsackieviruses (CVB4) [89], polioviruses [82,83] and rhinoviruses [80,81]. Additionally
five of the PIDVs had mutations mapped into N-terminal region which is suspected to be the 3A6
antibody binding site, and also it is known to be the binding site of the widely used EV antibody
(Dako, clone 5-D8/1, Agilent) which could influence immunostaining of persisting EV in tissue samples.
For example, 1.1B4 cells persistently infected with different CVB1 strains had less VP1 positivity in the
last time point, which may be due to mutation in AA28.
Mutations were rare in non-structural proteins. Two of them, 3B and 3C, were conserved and
remained intact. Additionally, the 3A had few mutations in some of the PIDVs. One of the 3A
mutations, H57Y in ATCC E1-PIDV[PANC-1], has been reported as linked to resistance to antiviral
drugs [60]. The 2A-C had mutations among the studied PIDVs, however, no variable region was
mapped in any of these proteins.
The 5′ UTR has domains I-VI and domain I is also called cloverleaf region, which plays a role in
viral RNA replication [90,91]. In the current analyses the cloverleaf region the read depth was below
10 in PIDV genomes obtained from NGS analysis making variant calling not possible. The domains
II-V have the internal ribosome entry site (IRES), having a role in translation [7]. The IRES has a
polypyrimidine tract, where the 40S ribosomal subunits bind [92]. Mutations at IRES may influence
virulence. As an example, in a site-directed mutagenesis study with CVB1, nt 573 and 579 within the
5′-UTR was mutated leading to significantly elevated virulence and pathogenesis of the virus [93].
Viral replication efficiency and viral virulence are also affected by proper folding and functioning of
the 5′-UTR [54]. In the current study several mutations were mapped into 5′-UTR and majority of the
mutations were not on highly reactive base pairs; however, the 10802-PIDV[PANC-1] and [1.1B4] both had
mutation mapped on highly reactive base pair (nt 234) [54].
The second open reading frame has been recently identified in human enteroviruses (Enteroviruses
A, B and C) [5,6]. It overturned the impression that EVs have only a single open reading frame.
The second ORF is translated into second ORF protein (ORF2p), which is a membrane-associated
protein that is localized to cytosolic vesicles. According to the latest studies ORF2p facilitates intestinal
infection and release of the viral particles from intestinal epithelial cells [6]. The conserved WIGHPV
domain, which is important for ORF2p-dependent intestinal infection [6], had a single AA substitution
on the WIGHPV conserved domain V18A in one of the PIDVs (10802-PIDV[1.1B4]). However, overall,
the ORF2p did not include any common mutations in persisting virus strains, but interestingly the
ORF2p has many differences between CVB1 strains.
The study utilizes two pancreatic cell lines, 1.1B4 beta cell line and PANC-1 pancreatic ductal cell
line, and four different CVB1 strains with different immunogenic properties [31]. We have previously
observed that CVB1 10796 strain is weakly stimulating in plasmacytoid dendritic cells whereas CVB1
Microorganisms 2020, 8, 1790 16 of 21
10802 strain is strongly immunogenic [31]. CVB1 10796 replicated also faster and produced significantly
higher amount of virus than CVB1 10802. The ATCC strain induces modest and CVB1 10797 only weak
innate immune response [31]. Altogether this study design, using different virus strains with different
phenotypic characteristics and two cell lines, increased the probability that the mutations that developed
in the majority of these models were linked to the development of persistency. These mutations are
potentially attractive targets for future studies using site-directed mutagenesis and other tools to study
their effect on virus biology in detail.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-2607/8/11/1790/s1,
Figure S1: Mutations on 2A, 2B and 2C non-structural proteins in all CVB1 PIDVs established in TP2. The location
and the corresponding amino acid substitution are shown in the top line and the corresponding PIDVs are
presented below. I50V in 2B, marked with grey color, is in hydrophobic domain of and K58R in hydrophilic
domain. M175L, marked with grey color in 2C is in ATPase motif B region, Table S1. The 50% endpoint titers
for CVB1 ATCC and CVB1 10796 viruses in PANC-1 cell model (in TCID50/mL) measured by TCID50 assay for
6.8 months post infection, Table S2. Human alignment is processed from Vipie virome pipeline [1] based on de
novo Velvet [2] contig mapping using minimum Kmer 51 (data is available upon request). The mean CVB/Human
Proportions of all samples are 13.01% (PANC-1 6.68% and 1.1B4 23.57%).
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